Axxam: A new generation screening collection (AXXDIV2.0) is now available for drug discovery programs
Bresso (Milan, Italy), September 23rd 2013 – Axxam S.p.A., a contract research and discovery company, announced today that an entirely new generation screening collection is now available for drug discovery programs: AXXDIV2.0 made up of around 240,000 carefully selected small molecules.
The selection of the compounds was carried out building on Axxam’s broad screening expertise and significant input was given by the Company’s team of medicinal and computational chemists to ensure that the identified screening hits may represent promising and favorable starting points for further optimization.
In order to meet the manifold needs of customers, the new screening collection AXXDIV2.0 includes three different subsets: Discovery Set (providing a scaffold based approach), Explorer Set (ensuring highest chemical diversity), and Probe Set (covering the fragment-like space). Enamine was chosen as the compounds supplier having one of the world’s largest, most diverse and novel screening collection. Through Axxam`s partnership with Enamine, building blocks for all the compounds can be provided to allow significant speed up of the hit expansion and optimization processes.
Dr. Doris Hafenbradl, VP Discovery Services, Axxam, said: “Key for any successful hit discovery program is the quality of the compound library. That’s why we put a major effort into assembling this compound collection and applied the most stringent filters to favor lead-like properties. With this new collection we are addressing the needs of our clients to provide novel chemistry combined with a flexible model of generating custom subsets. The feedback from our customers has been extremely positive.”
Axxam is a privately owned contract research and discovery company. The Company has developed a proven track record as a third party research and discovery services provider for the life science industry. In addition, Axxam conducts several discovery programs for selected targets which are carried out in partnership with other companies or non-profit organizations.
Dr. Doris Hafenbradl
t: +39 02 2105680